{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:03:00Z","timestamp":1794286980463,"version":"4.9.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008002","name":"Vancouver Coastal Health Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005614","name":"BC Cancer Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijgc.2026.104770","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:45:44Z","timestamp":1779259544000},"page":"104770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The levonorgestrel intrauterine device and ovarian cancer risk: a population-based study"],"prefix":"10.1016","volume":"36","author":[{"given":"Abigail","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0564-5751","authenticated-orcid":false,"given":"Helena","family":"Abreu do Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9470-8581","authenticated-orcid":false,"given":"Paramdeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4305-3009","authenticated-orcid":false,"given":"Janice S.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6003-485X","authenticated-orcid":false,"given":"Jessica N.","family":"McAlpine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9594-0545","authenticated-orcid":false,"given":"Gillian E.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2026.104770_bib1","doi-asserted-by":"crossref","unstructured":"Canadian Cancer Statistics Advisory in Collaboration With the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics: A 2022 Special Report on Cancer Prevalence. https:\/\/doi.org\/10.24095\/hpcdp.43.1.05. Accessed February 20, 2025","DOI":"10.24095\/hpcdp.43.1.05"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104770_bib2","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijgc.2026.104770_bib3","unstructured":"Ovarian epithelial, Fallopian tube, and primary peritoneal cancer treatment for health professionals (PDQ\u00ae). National Cancer Institute. https:\/\/www.cancer.gov\/types\/ovarian\/hp\/ovarian-epithelial-treatment-pdq. Accessed February 25, 2025"},{"issue":"10290","key":"10.1016\/j.ijgc.2026.104770_bib4","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"issue":"9609","key":"10.1016\/j.ijgc.2026.104770_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls","volume":"371","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104770_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/AOG.0b013e318291c235","article-title":"Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis","volume":"122","author":"Havrilesky","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104770_bib7","first-page":"587","article-title":"Trends in oral contraceptive and intrauterine device use among reproductive-aged women in the US from 1999 to 2017","volume":"32","author":"King","year":"2021","journal-title":"Cancer Causes Control"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104770_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/bmjsrh-2021-201260","article-title":"Time trends in contraceptive prescribing in UK primary care 2000\u20132018: a repeated cross-sectional study","volume":"48","author":"Pasvol","year":"2022","journal-title":"BMJ Sex Reprod Health"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104770_bib9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/ajo.13257","article-title":"Changes in use of hormonal long-acting reversible contraceptive methods in Australia between 2006 and 2018: a population-based study","volume":"61","author":"Grzeskowiak","year":"2021","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104770_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/aogs.13055","article-title":"Contraceptive use in the Nordic countries","volume":"96","author":"Lindh","year":"2017","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104770_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12905-025-03597-3","article-title":"Changes in Canadian contraceptive choices: results of a national survey on hormonal contraceptive use","volume":"25","author":"Campbell","year":"2025","journal-title":"BMC Womens Health"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104770_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2018.02.006","article-title":"Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC study","volume":"149","author":"Jareid","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104770_bib13","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/0284186X.2016.1175660","article-title":"Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube","volume":"55","author":"Soini","year":"2016","journal-title":"Acta Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104770_bib14","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jnci\/djae282","article-title":"Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers","volume":"117","author":"Tuesley","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104770_bib15","doi-asserted-by":"crossref","first-page":"450.e1","DOI":"10.1016\/j.ajog.2024.05.011","article-title":"Association of Levonorgestrel-Releasing intrauterine device with gynecologic and breast cancers: a national cohort study in Sweden","volume":"231","author":"Yi","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ijgc.2026.104770_bib16","article-title":"Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study","volume":"362","author":"Iversen","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104770_bib17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1186\/1471-2458-10-736","article-title":"Age at menarche in Canada: results from the National Longitudinal Survey of Children & Youth","volume":"10","author":"Al-Sahab","year":"2010","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104770_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/GME.0000000000000990","article-title":"Age at natural menopause and its associated factors in Canada: cross-sectional analyses from the Canadian Longitudinal Study on Aging","volume":"25","author":"Costanian","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.ijgc.2026.104770_bib19","series-title":"BC Cancer Registry Data","year":"2021"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104770_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ijc.33531","article-title":"Intrauterine device use and risk of ovarian cancer: results from the New England Case-Control study and Nurses\u2019 Health Studies","volume":"149","author":"Yang","year":"2021","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104770_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104770_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beem.2012.11.004","article-title":"History of oral contraceptive drugs and their use worldwide","volume":"27","author":"Christin-Maitre","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ijgc.2026.104770_bib23","unstructured":"Summary safety review - birth control hormone (levonorgestrel, LNG)-releasing systems that are placed into the uterus (intrauterine systems, IUS) - Mirena, Jaydess and Kyleena. Health Canada. Accessed February 25, 2025. https:\/\/hpr-rps.hres.ca\/reg-content\/summary-safety-review-detail.php?lang=en&linkID=SSR00177."},{"key":"10.1016\/j.ijgc.2026.104770_bib24","first-page":"45","article-title":"Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS","volume":"1","author":"Jensen","year":"2010","journal-title":"Int J Womens Health"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104770_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ajog.2023.03.039","article-title":"Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review","volume":"229","author":"Minalt","year":"2023","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104770_bib26","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/humrep\/der211","article-title":"The \u2018incessant menstruation\u2019 hypothesis: a mechanistic ovarian cancer model with implications for prevention","volume":"26","author":"Vercellini","year":"2011","journal-title":"Hum Reprod"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104770_bib27","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/ijc.22081","article-title":"Oral contraceptive and IUD use and endometrial cancer: a population-based case\u2013control study in Shanghai, China","volume":"119","author":"Tao","year":"2006","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104770_bib28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/ije\/26.3.496","article-title":"Intrauterine device use and endometrial cancer risk","volume":"26","author":"Sturgeon","year":"1997","journal-title":"Int J Epidemiol"},{"issue":"10333","key":"10.1016\/j.ijgc.2026.104770_bib29","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104770_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41379-019-0370-1","article-title":"Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions","volume":"33","author":"Wu","year":"2020","journal-title":"Mod Pathol."},{"issue":"22","key":"10.1016\/j.ijgc.2026.104770_bib31","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1158\/1078-0432.CCR-12-2155","article-title":"Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status","volume":"18","author":"George","year":"2012","journal-title":"Clin Cancer Res."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:47:57Z","timestamp":1785790077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26003014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1048891X26003014"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104770","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The levonorgestrel intrauterine device and ovarian cancer risk: a population-based study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104770"}}